TABLE 1.
Baseline patient, cancer, immune status, and anticancer therapy characteristics
| N = 87 | ||
|---|---|---|
| Age (years) | Median (range) | 12 (0‐24) |
| Sex, n (%) | ||
| Male | 48 (55) | |
| Female | 39 (45) | |
| Ethnicity, n (%) | ||
| Hispanic | 64 (74) | |
| Non‐Hispanic | 23 (26) | |
| Weight status | ||
| Overweight | 14 (16) | |
| Obese | 28 (32) | |
| Lean | 45 (52) | |
| Cancer, n (%) | ||
| Hem, n (%) | 63 (72) | |
| ALL | 53 | |
| AML | 2 | |
| Hodgkin | 2 | |
| NHL | 2 | |
| Other | 4 | |
| Non‐Hem, n (%) | 24 (28) | |
| Brain | 3 | |
| Sarcoma | 7 | |
| Neuroblastoma | 8 | |
| Wilms | 3 | |
| Retinoblastoma | 1 | |
| Other | 2 | |
| Therapy, n (%) | ||
| Chemo | 64 (74) | |
| HSCT | 12 (14) | |
| CAR | 7 (8) | |
| CAR & HSCT | 4 (4) | |
| Chemotherapy intensity (n = 64) a | ||
| Intense | 29 | |
| Nonintense | 35 | |
| HSCT type (n = 16) | ||
| Allogeneic | 10 | |
| Autologous | 6 | |
| Days since therapy, median (range) b | ||
| HSCT | 305 (−39 to 3939) | |
| CAR | 629 (21‐2142) | |
| Steroids c , n (%) | 18 (21) | |
| Anthracyclines, n (%) | 65 (75) | |
| Neutropenia d , n (%) | 14 (16) | |
| Lymphopenia e , n (%) | 35 (40) | |
| Any Comorbidity, n (%) | 51 (59) | |
| Neurological | 14 | |
| Cardiac | 9 | |
| Pulmonary | 5 | |
| Renal | 4 | |
| Endocrine | 4 | |
| Infection f | 8 | |
| Gastrointestinal | 10 | |
| Other | 19 | |
| GVHD | ||
| Acute | 1 | |
| Chronic | 2 | |
| Immune status (allo‐HSCT, n = 9) g | ||
| Lymphopenia | 0 | |
| Neutropenia | 0 | |
| CD4 < 200 | 0 | |
| Immune status (CAR, n = 8) g | ||
| Lymphopenia | 3 | |
| Neutropenia | 0 | |
| CD4 < 200 | 2 | |
| B‐cell aplasia | 7 | |
Intense: patients in the midst of a highly myelosuppressive phase of chemotherapy at the time of COVID‐19 infection.
Days: time interval between the date of last anticancer therapy (HSCT or CAR) and the date of the first positive COVID‐19 PCR.
Received systemic steroids (not including steroids given as part of COVID‐19 management) within 2 weeks prior to the date of COVID‐19 diagnosis.
Absolute neutrophil count <500.
Absolute lymphocyte count <500.
Includes 4 patients with non‐COVID viral infection and 4 patients with fungal infection.
Patients who had received both HSCT and CAR were classified as HSCT or CAR based on the last anticancer therapy prior to COVID‐19 infection.